-
Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK
Sep 9, 2025, 16:22 PM -
Uncovering the Cost Landscape of Congenital Heart Disease (CHD) With a Life Course Perspective: A Systematic Review of Healthcare Utilization by Lesion Type and Age
Sep 9, 2025, 16:22 PM -
A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain
Sep 9, 2025, 16:22 PM -
The Evolving Role of Pharmacists as Vaccinators in New Zealand and Denmark
Sep 9, 2025, 16:22 PM -
Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions
Sep 9, 2025, 16:22 PM -
Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025
Sep 9, 2025, 16:22 PM -
Measuring the Elephant in the Room: Quantifying Legal Barriers to AI Processing of Full?Text in Systematic Reviews
Sep 9, 2025, 16:22 PM -
Using Structured Expert Elicitation to Estimate Long-Term Organ Damage Risk in an Ultrarare Condition: A STEER Case Study
Sep 9, 2025, 16:22 PM -
CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?
Sep 9, 2025, 16:22 PM -
Occurrence of Exacerbations and Mortality in High-Risk Chronic Obstructive Pulmonary Disease Patients While on Treatment With Dual or Triple Inhaled Therapy: Results From the SIRIUS Observational Study in the US
Sep 9, 2025, 16:22 PM -
Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)
Sep 9, 2025, 16:22 PM -
Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments
Sep 9, 2025, 16:22 PM -
The Estimation of the Prevalent Presymptomatic Type 1 Diabetes Population in Germany Using a Patient Funnel Model
Sep 9, 2025, 16:22 PM -
Reassessing NICE's Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework
Sep 9, 2025, 16:22 PM -
Trends in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prescribing in England: A Data Analysis Using NHS Prescription Episodes Statistics (PES)
Sep 9, 2025, 16:22 PM -
How the NHS Can Optimize Health Outcomes in a Time of Financial Constraint
Sep 9, 2025, 16:22 PM -
Medical and Nonmedical Resource Utilization Associated With CIDP: Results From a Real-World International Survey
Sep 9, 2025, 16:22 PM -
Utility Estimates for Health States Associated With Immune Thrombocytopenia: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases
Sep 9, 2025, 16:22 PM -
The Phantom Menace: How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access
Sep 9, 2025, 16:22 PM